Skip to main content

Inductive Bio Launches Indy, AI Chemistry Agent Beating GPT-5.6, Claude Opus 5

Image
Inductive Bio Launches Indy, AI Chemistry Agent Beating GPT-5.6, Claude Opus 5

NEW YORK – September 17, 2026 -- Inductive Bio has launched Indy, an AI medicinal chemistry agent that scored 89% accuracy on 84 real-program dose-response curves, versus 48% for Claude Opus 5 and 39% for GPT-5.6 Sol run at maximum effort settings.

Indy has doubled chemist productivity inside live partner drug discovery programs

Inductive Bio built Indy internally with its medicinal chemists, computational chemists and DMPK scientists, then deployed it across active partner programs before today's public launch. The company reports the tool doubled team productivity by taking over data QC, SAR analysis, generative chemistry runs, FEP calculation setup and project-update slide generation.

Indy integrates with Inductive's benchmark-winning ADMET and PK models

The agent works directly with a program's existing data and computational tools, including Inductive's own ADMET and pharmacokinetic prediction models, to support daily decisions on assay reliability, structure-activity relationship trends, target product profile alignment and synthetic resource allocation.

Anvia Therapeutics has embedded Indy into data QC and synthesis queue management

"We have incorporated Indy into a number of workflows, including data QC, SAR table construction and analysis, and synthesis queue management," said Nicholas Perl, PhD, head of chemistry at Anvia Therapeutics. He said the tool surfaces data patterns that improve decision-making while reducing time spent on slide maintenance.

Head-to-head testing spanned 84 dose-response curves from live discovery programs

In the published benchmark, Indy was tested against Claude Opus 5 and GPT-5.6 Sol on real assay data drawn from active drug discovery programs. Indy's 89% accuracy rate outpaced both general-purpose large language models even when those systems were instructed to apply their highest reasoning effort levels.

Inductive Bio positions Indy as a fix for chemistry's decision bottleneck, not its ideation speed

Josh Haimson, co-founder and CEO of Inductive Bio, said the company trained Indy specifically on tasks that consume medicinal chemists' time without requiring their creative judgment. Indy is available to Inductive Bio's partners starting today.

Published by
fairsonline_team
Industries
Products
News Type